The cost-effectiveness of varicella vaccine programs for Australia

Scuffham, Paul Anthony; Lowin, Ana; Burgess, Margaret

doi:10.1016/s0264-410x(99)00261-3

Cited by 73 publications

(67 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two more articles were added 25,26 from periods studied by previous reviews 2,3 , plus four articles 27,28,29,30 published in 2008.…”

Section: Results Of Literature Searchmentioning

confidence: 99%

“…40,41 . One study was done in New Zealand 37 , one in Australia 25 , two in Taiwan 44,50 , one in Israel 46 , and one in Brazil 30 .…”

Section: Results Of Literature Searchmentioning

confidence: 99%

“…The majority of the studies (63%) adopted both perspectives (payer and society) 28,29,30,34,35,36,37,40,41,42,43,44,45,46,48,50,51,52 , one study included the patient's perspective 44 , and three did not conduct an analysis from society's perspective 25,26,41 .…”

Section: Results Of Literature Searchmentioning

confidence: 99%

See 2 more Smart Citations

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

2009

View full text Add to dashboard Cite

show abstract

“…Two more articles were added 25,26 from periods studied by previous reviews 2,3 , plus four articles 27,28,29,30 published in 2008.…”

Section: Results Of Literature Searchmentioning

confidence: 99%

“…40,41 . One study was done in New Zealand 37 , one in Australia 25 , two in Taiwan 44,50 , one in Israel 46 , and one in Brazil 30 .…”

Section: Results Of Literature Searchmentioning

confidence: 99%

See 1 more Smart Citation

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

2009

View full text Add to dashboard Cite

show abstract

“…Studies comparing immune responses following a one- or two-dose regime have shown that higher seroconversion rates and a higher antibody titer are achieved among subjects who receive two vaccine doses, regardless of the time interval between doses [59–62]. Nevertheless, cost-effectiveness modeling of two- versus one-dose schedules, suggesting that addition of a second dose demonstrates unfavorable incremental cost-effectiveness, has been instrumental in informing Australia’s decision to implement a one-dose schedule [55,63]. More recent modeling suggests that improving vaccine coverage, for example, from 83% to 95% by age 24 months, results in the incremental benefit of a second dose falling by 70% [64].…”

Section: Story Of Varicella Vaccine Developmentmentioning

confidence: 99%

Varicella and herpes zoster vaccine development: lessons learned

Warren‐Gash

Forbes

Breuer

2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Before vaccination, varicella zoster virus (VZV), which is endemic worldwide, led to almost universal infection. This neurotropic virus persists lifelong by establishing latency in sensory ganglia, where its reactivation is controlled by VZV-specific T-cell immunity. Lifetime risk of VZV reactivation (zoster) is around 30%. Vaccine development was galvanised by the economic and societal burden of VZV, including debilitating zoster complications that largely affect older individuals. Areas covered: We describe the story of development, licensing and implementation of live attenuated vaccines against varicella and zoster. We consider the complex backdrop of VZV virology, pathogenesis and immune responses in the absence of suitable animal models and examine the changing epidemiology of VZV disease. We review the vaccines’ efficacy, safety, effectiveness and coverage using evidence from trials, observational studies from large routine health datasets and clinical post-marketing surveillance studies and outline newer developments in subunit and inactivated vaccines. Expert commentary: Safe and effective, varicella and zoster vaccines have already made major inroads into reducing the burden of VZV disease globally. As these live vaccines have the potential to reactivate and cause clinical disease, developing alternatives that do not establish latency is an attractive prospect but will require better understanding of latency mechanisms.

show abstract

“…The vaccine has been licensed in many countries and in 1995 was introduced into the routine immunization schedule for healthy children in the United States [9]. Many other countries are currently studying the possibility of mass vaccination [10][11][12][13][14][15]. However, some important questions remain which limit the widespread acceptability of the vaccine in these countries.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of varicella zoster virus infection in Canada and the United Kingdom – CORRIGENDUM

Brisson¹,

Edmunds

Law³

et al. 2014

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYMany countries are currently studying the possibility of mass vaccination against varicella. The objective of this study was to provide a comprehensive picture of the pre-vaccine epidemiology of the varicella zoster virus (VZV) to aid in the design of immunization programs and to adequately measure the impact of vaccination. Population-based data including physician visit claims, sentinel surveillance and hospitalization data from Canada and the United Kingdom were analysed. The key epidemiological characteristics of varicella and zoster (age specific consultation rates, seasonality, force of infection, hospitalization rates and inpatient days) were compared. Results show that the overall epidemiology of varicella and zoster is remarkably similar between the two countries. The major difference being that, contrary to Canada, the epidemiology of varicella seems to be changing in the United Kingdom with an important decrease in the average age at infection that coincides with a significant increase in children attending preschool. Furthermore, differences exist in the seasonality between the United Kingdom and Canada, which seem to be primarily due to the school calendar. These results illustrate that school and preschool contact patterns play an important role in the dynamics of varicella. Finally, our results provide baseline estimates of varicella and zoster incidence and morbidity for VZV vaccine effectiveness and cost-effectiveness studies.

show abstract

The cost-effectiveness of varicella vaccine programs for Australia

Cited by 73 publications

References 17 publications

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

Varicella and herpes zoster vaccine development: lessons learned

Epidemiology of varicella zoster virus infection in Canada and the United Kingdom – CORRIGENDUM

Contact Info

Product

Resources

About